Interviews and Presentations
Batu Biologics Presents at Spotlight on JLABS Event
Batu Biologics was selected as one of the highlighted companies from the JLABS incubator facility in San Diego, CA. Mr. Samuel Wagner, President and CEO, discusses the company’s unique approach to treating cancer by targeting the tumor blood vessels with a potent, multi-pronged active vaccination.
Batu Biologics Introduces ValloVax Immunotherapy
Batu Biologics is a biotechnology-based pharmaceutical company focused on the development and commercialization of novel therapies that target the “Achilles Heel of Cancer”: the tumor blood vessels. Batu’s flagship therapeutic, ValloVax™, is an angiogenesis targeting cancer vaccine in the late stages of preclinical development. Batu Biologics has currently filed an Investigational New Drug Application (IND # 16296) for the initial indication of non-small cell lung cancer (NSCLC), and anticipates clinical approval to begin treating patients in Q3 of 2015.
Anti-angiogenic cancer vaccinations – a promising future for cancer immunotherapy
Samuel C. Wagner, President and CEO of Batu Biologics, discusses Facciponte’s study of a TEM-1 DNA vaccination’s efficacy as a cancer therapeutic and the affect of the vaccination on healthy angiogenesis processes in the body.
Batu Biologics Launches Indiegogo Crowdfunding Campaign for Novel Lung Cancer Therapy
Batu Biologics is pleased to announce the launch of its first crowdfunding campaign asking $100,000 to complete the preclinical studies for ValloVax, a novel cancer vaccine targeting the tumor blood vessels (endothelium).
Tumor Blood Vessels: Cancer’s Shield Against the Immune System?
Samuel Wagner, President and CEO of Batu Biologics, discusses the significance of the tumor endothelium as the first immunological barrier masking the tumor from detection and destruction by the host’s immune system.